This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...
CRA is a proud sponsor of the conference. Greg Bell speaks during the session titled “Damages in Pharma & Biotech Litigation: What Courts are Accepting...
CRA is a proud sponsor of the event for market access, reimbursement, and government policy experts. Ashley Fraser presents on “MFN – Implications in...
